When will the LOTEPREDNOL ETABONATE AND TOBRAMYCIN patents expire, and when will generic LOTEPREDNOL ETABONATE AND TOBRAMYCIN be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	LOTEPREDNOL ETABONATE AND TOBRAMYCIN	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	217597-001	Dec 10, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 26, 2026

The fixed-dose ophthalmic combination of loteprednol etabonate and tobramycin is a mature, generally low-cost therapeutic category with patent-driven generic risk that hinges on (1) formulation and method-of-use patent coverage in the Orange Book, (2) the remaining term of any “use” exclusivities tied to the NDA’s active ingredients, and (3) the breadth of any Paragraph IV litigation outcomes. From an investment standpoint, the fundamental drivers are the durability of branded share against generics in steroid-antibiotic eye drop classes, the ability to defend formulation and manufacturing IP, and the stability of ophthalmology prescribing volumes rather than blockbuster-like market expansion.

This analysis is structured for investors evaluating branded incumbents, generic challengers, and licensing targets tied to loteprednol etabonate plus tobramycin ophthalmic products.

What is the commercial and clinical profile for loteprednol etabonate plus tobramycin ophthalmic?

Primary value proposition: control of ocular inflammation with concurrent antibacterial coverage for susceptible bacterial conjunctivitis/ocular surface inflammation where clinicians choose a steroid-antibiotic combination rather than separate agents.

Category mechanics that matter for forecasting

Prescriber preference cycles: Ophthalmology tends to use combination products when they reduce dosing burden and may improve adherence versus separate steroid + antibiotic prescriptions.
Stewardship and label boundaries: Steroids drive payer scrutiny because of safety risks (e.g., increased IOP, cataracts, infection risk). Real-world utilization often concentrates in defined clinical scenarios and duration-of-therapy windows.
Competition from “equivalent” steroid/antibiotic stacks: Even when a combo product is biologically rational, therapeutic substitution can erode pricing power if generics or alternatives are available.

Where investor value concentrates

Pricing and share retention versus branded peers in the same class
Patent fence strength that delays generic erosion
Contracting status with large payers and formularies
Product line extensions and lifecycle management (reformulations, dosing regimens)

What patents protect loteprednol etabonate and tobramycin combination products in the US?

Featured snippet answer: Patent protection typically clusters in formulations, manufacturing methods, and method-of-use (including dosing regimens and sterile ophthalmic characteristics) rather than the core pharmacology of either ingredient.

How the patent estate usually maps

Drug substance or core compound patents
Loteprednol etabonate and tobramycin each have their own historical patent families. For an already marketed fixed combination, those early “composition of matter” terms often sit far enough in the past that the remaining enforcement window is mostly driven by later formulation/use patents.
Ophthalmic formulation patents
For drops and suspensions, the patent fence commonly includes:
- particle size, solubilization or suspension stability,
- excipient system,
- viscosity, pH, osmolality,
- container-closure compatibility and preservative strategy.
Manufacturing and sterilization process patents
- sterile filling approach,
- batch release specifications affecting uniformity and stability.
Method-of-use and dosing schedule patents
- treatment of specific ophthalmic indications,
- dosing frequency and duration,
- subpopulation use (e.g., post-surgical inflammation scenarios, where applicable).

Practical investment implication

If the Orange Book shows broad formulation or method-of-use coverage that remains unexpired, generic entrants face higher legal and regulatory execution risk.
If the Orange Book coverage is thin or concentrated in narrow use claims, generic erosion can accelerate with fewer barriers.

What is the Orange Book status of loteprednol etabonate and tobramycin ophthalmic products?

Featured snippet answer: The Orange Book status determines whether an applicant would need to certify to listed patents or can rely on unlisted claims. For investment modeling, focus on:

listed patents covering the specific marketed dosage form (e.g., suspension),
each patent’s expiration date,
whether there are pediatric exclusivities or additional 180-day exclusivity triggers.

Orange Book-driven milestones to build into a model

Listed patent expiration dates (first potential generic entry date)
“S” vs “P” exclusivity entries (non-patent exclusivity)
Any listed patents expiring after the earliest drug substance life (often formulation patents)

When does loteprednol etabonate plus tobramycin lose exclusivity?

Featured snippet answer: Exclusivity loss occurs in layers. Generic entry timing usually follows the earliest of:

patent expiration of the last listed relevant patent,
loss of any associated marketing exclusivity (NME: non-patent marketing exclusivity where applicable),
or an entry date accelerated by Paragraph IV settlements or court outcomes.

How to structure a credible timeline

Identify the last Orange Book listed patent tied to the specific combo product/dosage form.
Overlay any exclusivity end dates (if present).
Add expected regulatory lead time: typically NDA/ANDA manufacturing scale-up and stability package finalization after legal clearance.

Investment modeling takeaway

The “exclusivity end date” is not the same as the “margin squeeze start date.”
The margin squeeze usually starts after generic launch and payer contracting, often 3 to 12 months after legal clearance depending on distribution and interchangeability.

Which companies are challenging loteprednol etabonate and tobramycin with Paragraph IV ANDAs?

Featured snippet answer: Paragraph IV challengers are identifiable through ANDA litigation and FDA-Orange Book certification histories. Their risk profile depends on whether they attack formulation/use patents or rely on design-around.

Investor-relevant challenger dynamics

First-filer incentives: If a company is the first Paragraph IV filer, it may receive 180-day exclusivity (subject to statutory conditions).
Settlement likelihood: Steroid/antibiotic combination products often settle when patents are defensible enough to raise expected trial costs but narrow enough for design-around or licensing.
Non-infringement strategies: Some challengers aim for formulation/process changes that avoid claim coverage.

What patent litigation affects loteprednol etabonate plus tobramycin generic entry?

Featured snippet answer: Litigation timing and outcome dictate whether generic entry is delayed by:

preliminary injunctions,
final judgment sustaining validity and infringement,
or settlement agreements with agreed launch dates.

What to monitor for an investment “inflection”

Court decisions that uphold or invalidate key claims
Settlement terms specifying:
- “carve-out” timing for generic launch,
- permitted launch scopes (specific strength, dosage form, or labeling),
- cross-licenses.

Investment implication

The highest value updates come from settlements that push launch later than the earliest patent expiry, or from court outcomes that accelerate entry.

How strong is the patent estate for loteprednol etabonate and tobramycin products?

Featured snippet answer: Patent estate strength is a function of (1) claim breadth in remaining Orange Book-listed patents, (2) remaining term, and (3) litigation history credibility.

Investment scoring framework

Breadth: formulation claims that cover composition and stability across multiple embodiments are harder to design around than narrow method claims.
Time left: remaining term dictates whether litigation is “worth it” for generics.
Vulnerability signals: prior invalidity rulings, weak enablement histories, or narrow interpretation tendencies in related ocular formulation cases.

Practical conclusion for investors

A “strong estate” usually means multiple unexpired, formulation-anchored patents with consistent infringement narratives.
A “weak estate” usually means few listed patents, mostly narrow dosing/use claims, and historical generic market entry in the same class.

What formulations are protected by loteprednol etabonate and tobramycin patents?

Featured snippet answer: The protected subject matter for ophthalmic steroid-antibiotic combinations typically centers on the suspension/drop system rather than just the active ingredients.

Common protected elements in ophthalmic combo products

Active suspension characteristics (particle size and distribution)
Viscosity and wetting properties
Preservative compatibility and antimicrobial protection
pH and ionic strength to maintain drug stability and ocular comfort
Bottle design and stability over shelf life

Commercial relevance

If a competitor must reformulate significantly to avoid infringement, launch timelines slip.
If reformulation is feasible without clinical bridging, generic launch can be faster.

Are method-of-use patents a key risk for generics of loteprednol etabonate plus tobramycin?

Featured snippet answer: Method-of-use and dosing regimen patents can be outcome-determinative where labels remain tightly coupled to claim scope.

How use-code patents affect entry

A generic can potentially launch with “skinny labeling” that avoids infringement while still meeting approval requirements.
If the label cannot be narrowed without losing approved indications, or if claims are tied to core dosing, the generic face higher settlement pressure.

How does loteprednol etabonate plus tobramycin compare with alternative ophthalmic steroid-antibiotic products?

Featured snippet answer: The competitive advantage typically comes from label fit and dosing convenience rather than differentiated efficacy, because ophthalmic steroid-antibiotic outcomes overlap across products.

Comparison axes

Dosing frequency (clinical adherence)
Formulation (comfort, viscosity, tolerance)
Formulary placement (payer rebates and contracting)
Generic interchangeability (bioequivalence and labeling parity)

Investment relevance

If alternatives have easier generic paths (fewer remaining patents), substitution accelerates when generic entry is imminent for the combo product.

What generic entry risks exist for loteprednol etabonate plus tobramycin?

Featured snippet answer: Generic entry risk is driven by two variables: (1) remaining Orange Book patent coverage, and (2) whether design-around or skinny-label entry is feasible.

Generic entry risk checklist investors use

Are there multiple unexpired patents for the exact marketed dosage form?
Do claims cover core formulation features versus narrow embodiments?
Are there existing generic competitors in the class that indicate low legal friction?
Do litigation outcomes suggest claim robustness?

What regulatory status does the FDA hold for loteprednol etabonate and tobramycin products?

Featured snippet answer: FDA approval status is reflected through:

the NDA approval and labeling,
ANDA approvals for generics,
Orange Book patent listings tied to those approvals.

Investor modeling

If multiple ANDAs exist, legal clearance is already demonstrated or settled.
If few ANDAs exist, it may indicate patent friction or formulation complexity.

What are the key commercial fundamentals and revenue exposure considerations?

Featured snippet answer: Revenue exposure depends on whether the product remains primarily protected by patents and exclusivity, or whether generic penetration already exists in the channel.

Commercial fundamentals that drive performance

Channel penetration: retail vs specialty distribution
Payer behavior: formulary placement after generic introductions
Unit demand stability: ophthalmology prescribing tends to be steady absent major clinical guideline shifts
Price erosion curve: combination products frequently experience sharp post-launch price compression

Investment implications

If the product is already generic-substitutable in practice, upside is limited to share gains or lifecycle extensions.
If exclusivity/patents still bind the market, the valuation can hinge on time to first generic and likelihood of settlement.

What licensing deals or settlement agreements typically shape this market?

Featured snippet answer: For ophthalmic combo products, licensing and settlements typically:

define launch dates,
allow limited “design-around” by a generic,
provide non-exclusive rights in exchange for consideration and dismissal of claims.

How settlements should be interpreted for underwriting

Launch date in settlement overrides patent-expiry timing only if the agreement is binding.
Scope restrictions can preserve branded share longer than the earliest technical patent expiry.

What manufacturing and IP barriers can delay generic entry for ophthalmic combinations?

Featured snippet answer: For suspension-based ophthalmic products, manufacturing IP and stability requirements can delay ANDA-ready launches even after a legal window opens.

Operational constraints that matter

Stability and particle size distribution control
Preservative compatibility
Sterile filling process qualification
Container-closure system stability validation

Investor takeaway

Barriers slow execution, increasing the probability that branded pricing remains higher for longer following legal clearance.

Key Takeaways

Investment upside in loteprednol etabonate plus tobramycin is driven more by remaining Orange Book-listed patent term and litigation outcomes than by clinical differentiation.
Patent estate strength in this class typically concentrates in formulation, manufacturing, and narrow method-of-use claims, which determine whether generic challengers can design around or must settle.
Exclusivity loss is layered; generic entry timing usually follows the last relevant listed patent and any non-patent exclusivity, adjusted by settlements and court outcomes.
Revenue exposure is highly sensitive to time-to-generic-launch and payer contracting dynamics after launch.
Manufacturing and stability requirements for ophthalmic suspensions can prolong margin protection even when legal barriers thin.

FAQs

Do generics of loteprednol etabonate and tobramycin always need full clinical trials?

Typically not; ANDA pathways rely on bioequivalence and quality standards, with clinical work shifting to any labeling changes or bridging requirements tied to formulation differences.

Can a generic enter with skinny labeling for method-of-use patents in this combination?

It can if the label can be narrowed to avoid infringement while still supporting approved indications and meeting FDA requirements.

What matters more for launch timing: patent expiry dates or exclusivity end dates?

Both. The earliest enforceable bar depends on which listed patents are still valid and whether any non-patent exclusivity is attached to the approval.

How do settlements usually impact generic launch for ophthalmic steroid-antibiotic products?

Settlements often set a launch date and may restrict scope by strength, dosage form, or labeling, which can delay erosion beyond the earliest patent expiry.

What operational risks most often delay ophthalmic ANDA approvals for combination drops?

Suspension stability, particle size uniformity, preservative compatibility, and container-closure stability under shelf-life conditions.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. ANDA and 505(j) Application Basics. U.S. Food and Drug Administration.
FDA. Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration.

LOTEPREDNOL ETABONATE AND TOBRAMYCIN Drug Patent Profile

Which patents cover Loteprednol Etabonate And Tobramycin, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Loteprednol Etabonate And Tobramycin

AI Deep Research

Questions you can ask:

Summary for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

US Patents and Regulatory Information for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Loteprendol Etabonate and Tobramycin (Brand Combo Drug): Investment Scenario, Patent/Exclusivity Fundamentals, and Commercial Risk